Efficacy and Safety of BG00012 in MS
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00168701|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : November 15, 2007
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis||Drug: BG00012||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||260 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis|
|Study Start Date :||October 2004|
|Study Completion Date :||March 2006|
- The primary endpoint for the primary objective is the total number of MRI lesions at Weeks 12, 16, 20, and 24.
- The secondary endpoints will include measuring the changes in MRIs from baseline until Week 24, changes in other MS measurements q12 weeks, and the annualized relapse rate and proportion of changes at Weeks 24 and 48.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168701
Show 42 Study Locations
|Principal Investigator:||Ludwig Kappos, Prof||Kantonsspital Basel|
|Study Director:||Gilmore O'Neill, MB, MRCPI, MMedSc||Biogen|